Cipher Pharmaceuticals Inc.
CPHRF
$11.09
$0.28892.68%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 114.78% | 78.45% | 57.66% | 25.11% | 11.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 114.78% | 78.45% | 57.66% | 25.11% | 11.49% |
| Cost of Revenue | 197.61% | 167.28% | 127.57% | 25.58% | 9.34% |
| Gross Profit | 95.45% | 57.99% | 41.01% | 24.99% | 12.01% |
| SG&A Expenses | 218.27% | 172.89% | 125.59% | 68.33% | 18.87% |
| Depreciation & Amortization | 529.12% | 373.15% | 227.38% | 114.59% | -17.67% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 240.94% | 188.70% | 134.94% | 55.72% | 9.23% |
| Operating Income | -12.39% | -33.77% | -23.82% | -5.92% | 13.87% |
| Income Before Tax | -53.08% | -85.52% | -76.70% | -20.48% | 10.61% |
| Income Tax Expenses | 38.17% | 24.30% | -11.53% | 68.91% | 39.04% |
| Earnings from Continuing Operations | -46.27% | -59.23% | -43.36% | -51.08% | -19.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.27% | -59.23% | -43.36% | -51.08% | -19.36% |
| EBIT | -12.39% | -33.77% | -23.82% | -5.92% | 13.87% |
| EBITDA | 37.20% | 4.86% | 2.19% | 7.35% | 10.05% |
| EPS Basic | -48.91% | -60.00% | -42.55% | -49.02% | -17.23% |
| Normalized Basic EPS | -37.05% | -63.88% | -54.21% | -3.47% | 14.00% |
| EPS Diluted | -48.52% | -59.71% | -42.03% | -49.60% | -17.79% |
| Normalized Diluted EPS | -37.70% | -64.25% | -54.51% | -3.76% | 13.76% |
| Average Basic Shares Outstanding | 4.82% | 1.74% | -1.01% | -3.31% | -3.03% |
| Average Diluted Shares Outstanding | 4.71% | 1.58% | -1.35% | -3.00% | -2.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |